[New data on relations between residual hormonal modulability and medical treatment of breast adenocarcinoma].
D000230:Adenocarcinoma / Q000032:analysis / Q000628:therapy*; D000315:Adrenalectomy; D001943:Breast Neoplasms / Q000032:analysis / Q000628:therapy*; D002369:Castration; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011944:Receptors, Androgen / Q000032:analysis; D011959:Receptors, Estradiol; D011960:Receptors, Estrogen / Q000032:analysis; D011965:Receptors, Glucocorticoid / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D011987:Receptors, Steroid / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use
D004965:Estrogen Antagonists; D004967:Estrogens; D011944:Receptors, Androgen; D011959:Receptors, Estradiol; D011960:Receptors, Estrogen; D011965:Receptors, Glucocorticoid; D011980:Receptors, Progesterone; D011987:Receptors, Steroid; D013629:Tamoxifen
Dati recenti sul rapporto tra modulabilità ormonale residua e terapia medica dell'adenocarcinoma mammario.